BioMarin Pharmaceutical (NASDAQ:BMRN) Research Coverage Started at Sanford C. Bernstein
Sanford C. Bernstein initiated coverage on shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) in a research note issued to investors on Tuesday, The Fly reports. The brokerage issued an underperform rating and a $81.00 price target on the biotechnology company’s stock. Other research analysts also recently issued reports about the stock. BMO Capital Markets […]